Patent Application
20220346837
In the United States, there are approximately 1,400 reproductive endocrinologists (REs) and 450 in vitro fertilization (IVF) clinics to serve the rapidly growing segment of patients desiring fertility treatments. This small footprint creates insufficient throughput of fertility services, accordingly assisted reproduction cycles remain stagnant at approximately 250K assisted reproduction cycles per year despite millions of people needing treatment. It is estimated that <5% of the United States' fertility needs are being met today and without new methodologies to make assisted reproduction easier and automated, the current infrastructure will continue to fail the millions of people seeking treatment.
One of the many bottlenecks is the need for an oocyte retrieval. The oocyte retrieval is a critical component in the IVF, or egg freezing, process where mature, unfertilized oocytes are aspirated directly from ovarian follicles. This is an invasive surgical procedure requiring anesthesia (or conscious sedation), an operating room, and a highly specialized staff (physicians, nurses, embryology personnel) to perform the oocyte retrieval. During the procedure, a thin needle guided by an ultrasound probe is directed into the ovary where the eggs are aspirated, and then transferred to the embryology lab for identification. Mature oocytes are cryopreserved for future use, or fertilized with sperm. The RE performing the aspiration uses real-time ultrasound imaging to aspirate the follicles and avoid puncture of the intestines or major blood vessels. Due to the complexity, only REs are qualified to perform this procedure and spend three additional years in a RE fellowship after a four year residency in obstetrics and gynecology. If a simplified method of performing the aspiration was available, more doctors could perform the procedure and assisted reproduction could be made available to millions more.
Various embodiments include methods for non-invasive retrieval of viable (i.e., able to be fertilized) oocytes from the uterus via a combination of unique ovarian stimulation and uterine lavage technology. These steps eliminate the need for an invasive surgical procedure. Uterine lavage refers to a rinsing of the uterine cavity to collect samples (e.g., embryos, oocytes, sperm and cells from the ovaries, fallopian tubes, endometrial cavity and cervix) from the reproductive system.
Challenge of Uterine Lavage
The primary challenge of using uterine lavage for egg retrieval is the viability of the oocytes at the time of recovery; if eggs are not viable they have no clinical utility. In natural cycles (without ovarian stimulation), mature oocytes are ovulated from the ovaries and remain viable for 24 hours after ovulation, but it takes approximately four days (or 96 hours) for the eggs to reach the uterus from the fallopian tubes. At the time that oocytes reach the uterus, they are no longer viable. This is corroborated by Munne et al (2020) where unfertilized oocytes were collected from the uterus through uterine lavage but could not be fertilized in-vitro.
In the historical work of Munne et al, injectable gonadotropins were administered to stimulate multiple follicles in the ovaries for 9-12 days. Use of a gonadotropin antagonist (GnRH antagonist) was administered to keep oocytes in the ovaries and prevent early ovulation. When the oocytes were of sufficient maturity, an ovulatory trigger was administered to mature the eggs and fixed the time for intrauterine insemination (IUI), and the subsequent uterine lavage procedure. Five days after IUI, a uterine lavage procedure was scheduled when appropriately developed embryos (now called blastocysts) were expected to be in the uterus.
Novel Hormonal Stimulation Protocol—Early Follicular Release
The inventors have developed a novel hormonal protocol to make possible the collection of viable oocytes from the uterus after a uterine lavage cycle. This protocol involves use of injectable gonadotropins over a 3-9 day period, and may also include a GnRH antagonist to prevent early unsynchronized release of oocytes. Immature oocytes (i.e. germinal vesicle and metaphase I) are released from the ovaries and traverse the fallopian tubes en route to the uterus. During transit, immature oocytes will mature in the fallopian tubes and reach the uterus at such time when the oocytes are mature and capable of fertilization. The uterine lavage should occur approximately 3-7 days after the ovulatory trigger.
The optimized protocol for non-invasive oocyte retrieval is as follows:
Novel Hormonal Stimulation Protocol—Accelerated Tubal Transport
The inventors have also developed an additional novel hormonal protocol to make possible the collection of viable oocytes from the uterus after a uterine lavage cycle. This protocol involves use of injectable gonadotropins over a 3-11 day period, applying a GnRH antagonist to prevent early ovulation, and application of an ovulatory trigger at a follicular diameter size of >10 mm. Approximately 36 hours after trigger, mature and immature oocytes (i.e. germinal vesicle and metaphase I) are released from the ovaries and traverse the fallopian tubes en route to the uterus. Approximately 0-36 hours after ovulation trigger, either Prostaglandins, Estradiol, and/or Progesterone Blockers will be administered to accelerate fallopian tube transport. Prostaglandins, Estradiol and/or Progesterone Blockers will increase ciliary movement and smooth muscle contraction to promote movement of the oocytes through the fallopian tubes. It is important to keep estrogen elevated after ovulation because it promotes ciliogenesis, increased tubal fluid, ciliary movement, and smooth muscle contraction. Progesterone levels, however, should be minimized after ovulation as progesterone inhibits ciliary movement and relaxes smooth muscle tissue. This is counterintuitive as in natural cycles and in IVF high estrogen is important for events prior to ovulation such as follicular growth and ovulation; after ovulation estrogen decreases and progesterone increases. Progesterone is involved in smooth muscle relaxation, ciliogenesis inhibition and prepares the endometrium for implantation and will have the opposite effects to estrogen in terms of fallopian tube transport. The inventors have a unique need to reverse the traditional endocrine profile of estrogen/progesterone after ovulation to make possible non-surgical oocyte retrieval. This protocol also has the additional benefit of creating a thinner endometrial layer which is a simpler environment from which to lavage from.
With the above modification, fallopian tube transport will be complete over 10-100 hours after ovulation trigger and oocytes reach the uterus at such time when the oocytes are mature and capable of fertilization. The uterine lavage could occur approximately 24-108 hours after the ovulatory trigger.
The optimized protocol for non-invasive oocyte retrieval is as follows:
Benefits of the Protocol
Oocytes recovered via uterine lavage can be fertilized for in vitro fertilization, or they can be cryopreserved for future use. Use of any of the above protocols protocol in combination with uterine lavage can provide a safer, less invasive alternative to oocyte aspiration. Uterine lavage addresses the current shortage of available reproductive services by allowing non-REs to collect oocytes with an office based procedure not requiring anesthesia. Thus, use of a novel stimulation protocol followed by uterine lavage has the potential to expand fertility care and lower cost.
In one embodiment of the present invention described above, a kit having instructions for use for performing uterine lavage in a female patient is disclosed which comprises a uterine lavage catheter configured for insertion into a woman's uterus to remove mature oocytes from the uterus; and at least a first container containing a sufficient dosage amount of an injectable gonadotropin (Gonal F or Follistim or Menopur) to induce superovulation and produce a plurality of mature oocytes in the women's uterus over a period of 3 to 11 days, wherein the kit does not include a GnRH antagonist. The injectable gonadotropin may be provided in a sufficient dosage amount to stimulate the ovaries and trigger the production of multiple oocytes over a shortened time period as compared to standard IVF protocols, e.g., over a period of 3 to 11 days. The kit may include instructions for use for administering the gonadotropins by self-injection, in which the dosage amount of injectable gonadotropin is appropriate for induction of superovulation, in vivo fertilization, and oocyte maturation. For example, the kit may include instructions for use for self-injecting the gonadotropin using 3 to 11 daily injections at ranges of 37.5 to 300 IU per day, e.g., at a total dosage amount of between 500 to 10000 IU's over the course of the superovulation protocol. The kit may further include one or more agents to accelerate tubal transport of the mature oocytes, wherein the one or more agents may comprise, e.g., a progesterone receptor blocker, estradiol, and/or a prostaglandin, for example, a progesterone receptor blocker at a dosage amount of between 100-2,000 mg, estradiol at a dosage amount of between 2-10 mg/day, and/or a prostaglandin at a dosage amount of between 20-1600 mg.
The kit may further include instructions for use for administering a single or multiple doses of urinary or recombinant hCG nasally, orally, subcutaneously, intramuscularly, transdermally, vaginally, rectally, or buccal route to induce ovulation. The kit may also include a second container or vial for storing and cryopreserving the recovered oocytes following the lavage procedure. Both of the one or more first and second containers may comprise an electronic or other coding label including the drug and any oocyte personal identification information.
The kit may further comprise instructions for use for performing at least one molecular diagnostic assay test on one or more of the recovered oocytes following recovery of oocytes from the uterus. The kit may comprise at least one instrument or agent for performing a biopsy from the one or more recovered oocytes. For example, the instrument may comprise a holding tool to stabilize one or more of the recovered oocytes during the biopsy procedure. The instrument may also comprise a control kit to ensure there is no contamination in the biopsied cells. The kit may further comprise a micropipette for performing the biopsy and removing the cells from the oocytes. The kit can include instructions for use for processing and handling (e.g., cryopreserving) the biopsied cells.
Other possible components of the kit include uterine lavage media, a consumable device which interfaces with an automated egg freezing machine such as the Gavi Automated Vitrification System (Geneabiomedx), cryogenic straws for storage of cryopreserved oocytes, a filter for facilitating the search for recovered oocytes following recovery from the uterus, an automated sperm processing kit for preparing sperm for IVF, a controller for controlling the pressure and vacuum applied to the uterine lavage catheter, catheter introducers, a pump and/or vacuum system and/or tubes, a cell culture vial for containing the oocytes following recovery and which maintains optimal CO2/O2 concentration for oocyte culture without the requirement of an incubator, or other cell-culture devices. The kit may be in packaged combination, such as in a pouch, bag or the like. The kit may further include instructions for the use of components of the kit in a uterine lavage procedure, such as instructions for use of the compounds to induce superovulation while stimulating the ovaries with injectable gonadotropins.
In another aspect of the invention, a composition suitable for administration to a human female patient during superovulation is disclosed to lead to the production of mature oocytes in the uterus of the patient. The composition may include human injectable gonadotropins (FSH and/or LH) in an amount sufficient to stimulate the ovaries at a dosage amount of about 500 to 10000 IU's over the course of treatment, e.g., in an amount sufficient to apply about 37.5-300 IU over 3 to 11 days. The injectable gonadotropins may include Gonal-F, Menopur, Novarel, Ovidrel, Pregnyl, Profasi, Chorex. Carriers may include aqueous solutions including saline, aqueous solutions including dextrose, water and buffered aqueous solutions, as well as oral formulations of the gonadotropins.
Methods are provided for administering an effective amount of the compositions (e.g., orally, nasally, intramuscularly, subcutaneously) to a patient to cause superovulation leading to the production of multiple mature oocytes in the uterus. For example, a method of inducing superovulation in a female patient to produce a plurality of mature oocytes in the uterus is disclosed which comprises administering injectable hCG to the patient to trigger superovulation, and gonadotropins that are administered daily for up to nine days or until the oocytes are at or between 8-18 mm in diameter as confirmed by ultrasound imaging of the ovaries. The method can include administering the gonadotropin over a period of between 3-11 days. For example, the method can include administering the gonadotropin over a period of three to six days. The gonadotropin may be administered at a dosage amount of between about 37.5 to 300 IU per day over a period of 3 to 11 days, e.g., the gonadotropin is administered at a dosage amount of about 150 IU per day over the first three days and 100 IU per day over the following 6-8 days.
| Number | Date | Country | |
|---|---|---|---|
| 63258422 | May 2021 | US |
